Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-amlodipine is the pharmacologically active (levorotatory, or "R") enantiomer of amlodipine, a long-acting dihydropyridine calcium channel blocker. Unlike standard amlodipine formulations, which are racemic mixtures of both R- and S-enantiomers, r-amlodipine contains only the R-enantiomer, which is responsible for the majority of the drug's therapeutic vasodilatory effects. Its mechanism of action involves inhibition of L-type calcium channels in vascular smooth muscle, leading to decreased peripheral vascular resistance, reduced blood pressure, and relief of cardiac workload. The clinical aim of r-amlodipine (versus racemic amlodipine) is to achieve the same or greater antihypertensive and antianginal effects at lower doses, possibly with fewer side effects such as peripheral edema. It is primarily used for the management of hypertension and chronic stable angina.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on r-amlodipine.